Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Thursday, July 6, 2023
Current investigative efforts have been directed at establishing a technique to assess the quality of life in patients with metastatic breast cancer who are undergoing combination treatment with the CDK/4/6 inhibitor palbociclib and endocrine therapy, explained Nadia Harbeck, MD, of Ludwig-Maximilians-University Hospital, Munich, and colleagues. The randomized PreCycle trial confirmed the efficacy of the CANKADO-based electronic patient-reported outcomes assessment in this patient population, according to a presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 1008).
From 2017 to 2021, a total of 412 patients with locally advanced or metastatic breast cancer were recruited for the study. Based on their previous therapy, patients were randomly assigned to either the active (CANKADO PRO-React, n = 271) or inactive (limited CANKADO functionality, n = 141) arms.
The study findings revealed a decreased risk of a deteriorated quality of life for patients in the CANKADO-active arm (hazard ratio = 0.6982). In addition, the authors reported an 80% completion rate of the Functional Assessment of Cancer Therapy–General questionnaire. Although the mean total scores did not significantly differ between treatment groups, when compared with baseline, the patients in the CANKADO-active group had a linear decline in their risk of deteriorated quality of life. Furthermore, the median progression-free survival was 21.4 months versus and 18.7 months with the CANKADO-active and -inactive groups, respectively. Moreover, patients in the CANKADO-inactive group had a median overall survival of 42.6 months. The median overall survival for patients in the CANKADO-active group has yet to be reached.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
